ストックスクリーナーアプリを入手
159.20
0.26%
0.42
Astrazeneca Plc (AZN) 最新ニュース
Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results - Zacks Investment Research
Form 4 ASTRAZENECA PLC For: 8 October By Investing.com - Investing.com UK
How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings? - Zacks Investment Research
Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3? - Zacks Investment Research
AstraZeneca (LSE:AZN) Opened A $1 Billion R&D Center In Kendall Square - Yahoo Finance
Jefferies maintains 'buy' rating on AstraZeneca ahead of third-quarter results - Proactive financial news
AstraZeneca PLC : Buy rating from Berenberg - www.marketscreener.com
US bank expects AstraZeneca to beat third-quarter forecasts as path clears to key lung cancer data - Proactive Investors
AstraZeneca PLC : Jefferies gives a Buy rating - www.marketscreener.com
AstraZeneca PLC : Bernstein reaffirms its Buy rating - www.marketscreener.com
AstraZeneca Takes Drug-Pricing Law Challenge To 4th Circ. - Law360
Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider - Zacks Investment Research
AstraZeneca’s Real World COPD Study in Russia Signals Strategic Respiratory Focus - TipRanks
AstraZeneca advances Tuesday, outperforms market - MarketWatch
Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity? - Zacks Investment Research
Citi raises AstraZeneca target to £186 as tozorakimab prospects improve - Proactive financial news
AstraZeneca opens new R&D centre in Cambridge, US - Pharmaceutical Technology
AstraZeneca Invests Over $1bn in Massachusetts - marketscreener.com
AstraZeneca Launches Research, Development Center in US - marketscreener.com
‘We’re here at the party now:’ AstraZeneca opens new Kendall hub with big hiring plans - The Business Journals
AstraZeneca CEO Soriot says drugmaker can grow without big acquisition - Seeking Alpha
AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment - CNBC
AstraZeneca to invest over $1 billion in Massachusetts, boost workforce - marketscreener.com
AstraZeneca to invest over $1B in Massachusetts ops - Breakingthenews.net
A Massachusetts investment will expand AstraZeneca’s state workforce by over 50% in coming years. - Stock Titan
AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts - Financial Times
AstraZeneca PLC (ZEG.DE) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Summit Therapeutics Closes $2 Billion AstraZeneca Investment - grafa.com
SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos - TradingView
SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos - Zacks Investment Research
FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line Setting - Zacks Investment Research
AstraZeneca completes USD2 billion Summit investment - marketscreener.com
Cancer-drug partnerships accompany AstraZeneca (AZN)'s completed investment in Summit. - Stock Titan
AstraZeneca Finalizes $2 Billion Investment in Summit Therapeutics - marketscreener.com
AstraZeneca has put $2 billion into Summit to support work on an experimental cancer treatment. - Stock Titan
REGAstraZeneca PLCAstraZeneca completes equity investment in Summit - TradingView
AstraZeneca completes equity investment in Summit Therapeutics - AstraZeneca
AstraZeneca PLC (ZEG.SG) stock price, news, quote and history - Yahoo Finance Australia
AstraZeneca PLC, Daiichi Sankyo And Summit Therapeutics Inc. Announce Clinical Collaboration To Evaluate Datroway In Combination With Ivonescimab Across Multiple Tumour Types - marketscreener.com
Summit Deal Could Help Futureproof AstraZeneca’s Datroway - insights.citeline.com
AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pact - Pharmaceutical Technology
AstraZeneca, Daiichi Sankyo Expand Cancer Push Through Summit Partnership - benzinga.com
Sanofi, Regeneron Expand Immunology Alliance With New Antibodies - Zacks Investment Research
Summit Teams Up With Daiichi Sankyo, AstraZeneca For Cancer Therapy Trial – CEO Calls It An ‘Important Expansion’ - Yahoo Finance
Lung and breast cancers are targets of AstraZeneca (AZN)'s new three-company trial collaboration. - Stock Titan
Europe Cancer Metabolism Based Therapeutics Market Forecast to 2035 by Modality, Route, Indication, and Therapy Sales | 25.3% CAGR Drives an $8.54 Billion Opportunity - GlobeNewswire Inc.
AstraZeneca, Daiichi Partner With Summit on Cancer-Drug Trials - Bloomberg.com
AstraZeneca and two partners plan to test a cancer-drug pairing in breast cancer - Stock Titan
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination - Reuters
AstraZeneca, Daiichi Sankyo collaborate with Summit Therapeutics to evaluate Datroway-ivonescimab combo - Seeking Alpha
1.82%
大文字化:
|
ボリューム (24 時間):